Mohammed Mostafa Keshawy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Mostafa Keshawy has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hoda E. Mohamed
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
2 shared publications Mervat E. Asker
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt
2 shared publicationsMona K. Tawfik
Department of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2 shared publications- Mona Kamal Tawfik
Department of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2 shared publications - Samy Makary
Department of Physiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2 shared publications Yasmin K. Mahmoud
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt
2 shared publications
Latest Publications
- 28 September 2024
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 27 (9) , 50-57
Correlation between Iron Overload and Glycemic Abnormalities among Thalassemia Patients Attending Suez Canal University Hematology Outpatient - Clinic
Background: Thalassemia is one of the commonest hemoglobinopathies in the world. Frequent blood transfusions are recommended for transfusion-dependent thalassemia. The human body lacks a physiological mechanism to eliminate excess iron load following a blood transfusion. Excess iron accumulates particularly in the liver, heart, and endocrine organs. Diabetes mellitus is one of the endocrine complications. Three main processes—insulin resistance, insulin insufficiency, and hepatic dysfunction—are thought to be involved in its development. Aim: early detection of glycemic abnormalities in patients with thalassemia to prevent its complications and start early and proper management. Subjects and Methods: This was an analytical cross-sectional study conducted over 67 patients attending the hematology outpatient clinic of Suez Canal University Hospital, Ismailia, Egypt, in the period between March 1 and June 10, 2022. Additionally, the patients included were all thalassemic patients of both sexes aged more than 12 years old with exclusion of type 1 Diabetes Mellitus patients and chronic liver disease patients. Results: Our study demonstrated that 19.4% were diabetic and 35.8% were prediabetic among thalassemia patients according to fasting glucose. On the other hand, regarding assessment of insulin resistance using homeostatic model assessment (HOMA-IR), 3 % of our study sample was within the border line range and 14.9% has HOMA IR more than 2. Conclusion: Our study concluded that iron overload is considered a risk factor for developing glycemic abnormalities in thalassemia patients which is most probably caused by inadequate chelation that led to hemosiderosis of the pancreas and other organs
- 28 September 2024
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 27 (9) , 50-57
Correlation between Iron Overload and Glycemic Abnormalities among Thalassemia Patients Attending Suez Canal University Hematology Outpatient - Clinic
Background: Thalassemia is one of the commonest hemoglobinopathies in the world. Frequent blood transfusions are recommended for transfusion-dependent thalassemia. The human body lacks a physiological mechanism to eliminate excess iron load following a blood transfusion. Excess iron accumulates particularly in the liver, heart, and endocrine organs. Diabetes mellitus is one of the endocrine complications. Three main processes—insulin resistance, insulin insufficiency, and hepatic dysfunction—are thought to be involved in its development. Aim: early detection of glycemic abnormalities in patients with thalassemia to prevent its complications and start early and proper management. Subjects and Methods: This was an analytical cross-sectional study conducted over 67 patients attending the hematology outpatient clinic of Suez Canal University Hospital, Ismailia, Egypt, in the period between March 1 and June 10, 2022. Additionally, the patients included were all thalassemic patients of both sexes aged more than 12 years old with exclusion of type 1 Diabetes Mellitus patients and chronic liver disease patients. Results: Our study demonstrated that 19.4% were diabetic and 35.8% were prediabetic among thalassemia patients according to fasting glucose. On the other hand, regarding assessment of insulin resistance using homeostatic model assessment (HOMA-IR), 3 % of our study sample was within the border line range and 14.9% has HOMA IR more than 2. Conclusion: Our study concluded that iron overload is considered a risk factor for developing glycemic abnormalities in thalassemia patients which is most probably caused by inadequate chelation that led to hemosiderosis of the pancreas and other organs
- Open Access
- 1 February 2023
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 19 (5) , 1508-1519
Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model
Introduction: Obesity is one of the most burdensome health problems and is closely linked to leptin resistance. The study examined whether an alternate-day high-fat diet (ADF) and/or GLP-1 agonist (exenatide) modulate brain leptin resistance caused by a high-fat diet (HFD).Material and methods: Sixty adult male mice were divided into 6 groups: (i) normal palatable diet (NPD), (ii) exenatide control (NPD received exenatide) (iii) HFD, (iv) ADF treated, (v) exenatide treated, (vi) ADF and exenatide treated. All animal groups were fed a HFD for 8 weeks, before they received treatment (ADF and/or exenatide) for 8 additional weeks. Body weight was assessed at the start and at the end of the experiment. Lipid profile, brain leptin and its receptor expression with the leptin-sensitive pathway, JAK2/STAT3/SOCS3/PTP1B, fasting blood glucose (FBG), serum insulin, liver metabolic handling via its regulators IRS1/PI3K/GLUT4 for hyperinsulinemia/obesity-induced PDK3/NAFLD2 modification, and liver enzymes were determined at the end of the experiment.Results: ADF and exenatide reduced body weight and FBG in HFD-obese mice (p < 0.05). The combined ADF and exenatide regimen enhanced the brain anorexic leptin/JAK2/STAT3 and attenuated the SOCS3/PTP1B pathway (p < 0.05). The ADF/exenatide anorexigenic brain effect also modulated liver glucose via IRS1/PI3K/GLUT4 expression (p < 0.05), attenuating NAFLD2 and PDK3 expression (p < 0.05). Liver enzymes and the histopathological profile confirmed the improvement.Conclusions: In HFD caloric consumption, a combination of ADF and GLP-1 agonist enhances the brain leptin anorexigenic effect with the improvement of the metabolic sequelae of hyperinsulinemia, hyperlipidemia and liver steatosis.
- 1 February 2023
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 19 (5) , 1508-1519
Open AccessAlternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model
Introduction: Obesity is one of the most burdensome health problems and is closely linked to leptin resistance. The study examined whether an alternate-day high-fat diet (ADF) and/or GLP-1 agonist (exenatide) modulate brain leptin resistance caused by a high-fat diet (HFD).Material and methods: Sixty adult male mice were divided into 6 groups: (i) normal palatable diet (NPD), (ii) exenatide control (NPD received exenatide) (iii) HFD, (iv) ADF treated, (v) exenatide treated, (vi) ADF and exenatide treated. All animal groups were fed a HFD for 8 weeks, before they received treatment (ADF and/or exenatide) for 8 additional weeks. Body weight was assessed at the start and at the end of the experiment. Lipid profile, brain leptin and its receptor expression with the leptin-sensitive pathway, JAK2/STAT3/SOCS3/PTP1B, fasting blood glucose (FBG), serum insulin, liver metabolic handling via its regulators IRS1/PI3K/GLUT4 for hyperinsulinemia/obesity-induced PDK3/NAFLD2 modification, and liver enzymes were determined at the end of the experiment.Results: ADF and exenatide reduced body weight and FBG in HFD-obese mice (p < 0.05). The combined ADF and exenatide regimen enhanced the brain anorexic leptin/JAK2/STAT3 and attenuated the SOCS3/PTP1B pathway (p < 0.05). The ADF/exenatide anorexigenic brain effect also modulated liver glucose via IRS1/PI3K/GLUT4 expression (p < 0.05), attenuating NAFLD2 and PDK3 expression (p < 0.05). Liver enzymes and the histopathological profile confirmed the improvement.Conclusions: In HFD caloric consumption, a combination of ADF and GLP-1 agonist enhances the brain leptin anorexigenic effect with the improvement of the metabolic sequelae of hyperinsulinemia, hyperlipidemia and liver steatosis.
- Open Access
- 1 January 2023
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 26 (1) , 47-54
Tissue Expression of Protease Activated Receptor 2 in Patients with Pruritus in Chronic Kidney Disease
Background: Uremic pruritus has been defined as itching that is directly related to kidney disease, without any other comorbid condition that causes itching. The exact pathogenesis of uremic pruritus remains unclear but, protease-activated receptor 2 (PAR2) is claimed to have a pivotal role in the pathogenesis of uremic pruritus. Aim: Evaluation of PAR2 activity in the epidermis of patients with chronic kidney disease (CKD) complaining of pruritus. Subjects and Methods: Case-control study on 48 individuals (24 CKD patients complaining from pruritus and 24 matched healthy controls). Skin biopsy specimens from all participants were taken from a similar area of the back of forearms then immunohistochemical analysis for PAR2 activity in the epidermis was performed. Results: Data revealed that epidermal PAR-2 expression was significantly higher in CKD patients compared to healthy controls. PAR2 staining intensity in skin biopsies was moderate in 9 (37.5%) patients and strong in 15 (62.5%) patients in the cases group. On the other hand, PAR2 staining was moderate in all 24 (100%) cases in the control group which was statistically significant.Conclusion: Epidermal PAR-2 expression is increased in CKD patients with pruritus.
- 1 January 2023
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 26 (1) , 47-54
Open AccessTissue Expression of Protease Activated Receptor 2 in Patients with Pruritus in Chronic Kidney Disease
Background: Uremic pruritus has been defined as itching that is directly related to kidney disease, without any other comorbid condition that causes itching. The exact pathogenesis of uremic pruritus remains unclear but, protease-activated receptor 2 (PAR2) is claimed to have a pivotal role in the pathogenesis of uremic pruritus. Aim: Evaluation of PAR2 activity in the epidermis of patients with chronic kidney disease (CKD) complaining of pruritus. Subjects and Methods: Case-control study on 48 individuals (24 CKD patients complaining from pruritus and 24 matched healthy controls). Skin biopsy specimens from all participants were taken from a similar area of the back of forearms then immunohistochemical analysis for PAR2 activity in the epidermis was performed. Results: Data revealed that epidermal PAR-2 expression was significantly higher in CKD patients compared to healthy controls. PAR2 staining intensity in skin biopsies was moderate in 9 (37.5%) patients and strong in 15 (62.5%) patients in the cases group. On the other hand, PAR2 staining was moderate in all 24 (100%) cases in the control group which was statistically significant.Conclusion: Epidermal PAR-2 expression is increased in CKD patients with pruritus.
- Open Access
- 16 July 2022
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
Urinary Monocyte Chemoattractant Protein -1 as A Diagnostic Marker of Lupus Nephritis
Background: Lupus nephritis accounts for significant morbidity and mortality in patients with systemic lupus erythematosus (SLE). Many biomarkers for renal involvement in SLE have been suggested in Egyptian patients; one of them is Monocyte chemoattractant protein-1 (MCP-1) which is one of the key chemokines that has chemotactic effect for monocytes and macrophages to sites of inflammation and may share in the pathogenesis of lupus nephritis (LN).Aim: The study aimed at assessing the role of MCP-1 in the early diagnosis of lupus nephritis and to explore any correlation its levels with disease activity and renal status. Methods: The study was done as a case control study where 60 SLE patients with lupus nephritis (30 patients with active LN and 30 patients with inactive LN) in addition to 30 healthy volunteers as control group were enrolled in the study and MCP-1 levels was determined using ELISA technique.Results: The majority of the studied patients were females representing 93.33 % of the studied population. Urinary MCP-1 levels in overall SLE studied patients groups was significantly higher than its level in control group (P value 0.0001) and it was significantly higher in active LN than in non-active LN subgroups (P value =0.0001). and it is significantly associated with C3 , C4 and ACR. Conclusion: Urinary MCP-1 can be used as a marker for LN activity .Keywords: SLE , Lupus nephritis , MCP-1
- 16 July 2022
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
Open AccessUrinary Monocyte Chemoattractant Protein -1 as A Diagnostic Marker of Lupus Nephritis
Background: Lupus nephritis accounts for significant morbidity and mortality in patients with systemic lupus erythematosus (SLE). Many biomarkers for renal involvement in SLE have been suggested in Egyptian patients; one of them is Monocyte chemoattractant protein-1 (MCP-1) which is one of the key chemokines that has chemotactic effect for monocytes and macrophages to sites of inflammation and may share in the pathogenesis of lupus nephritis (LN).Aim: The study aimed at assessing the role of MCP-1 in the early diagnosis of lupus nephritis and to explore any correlation its levels with disease activity and renal status. Methods: The study was done as a case control study where 60 SLE patients with lupus nephritis (30 patients with active LN and 30 patients with inactive LN) in addition to 30 healthy volunteers as control group were enrolled in the study and MCP-1 levels was determined using ELISA technique.Results: The majority of the studied patients were females representing 93.33 % of the studied population. Urinary MCP-1 levels in overall SLE studied patients groups was significantly higher than its level in control group (P value 0.0001) and it was significantly higher in active LN than in non-active LN subgroups (P value =0.0001). and it is significantly associated with C3 , C4 and ACR. Conclusion: Urinary MCP-1 can be used as a marker for LN activity .Keywords: SLE , Lupus nephritis , MCP-1
- 24 August 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (9) , 6457-6470
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression
Background Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM) and is associated with early changes in renal angiotensin II (ANG II). These changes were evaluated using ANG II blocker valsartan early from week two of diabetes (experiment I, renoprotective) and late from week nine of diabetes (experiment II, renotherapeutic) to the end of both experiments at week twelve. Methods and results In both experiments, adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, diabetic rats received valsartan treated in experiments I and II. DM effects on urine albumin excretion, blood pressure, and renal ANG II were measured. Urinary nephrin, kidney injury molecule-1 (KIM-1), renal angiopoietin-like protein 2 (ANGPTL2), and toll-like receptor 4 (TLR 4) mRNA expression were tested. DM-initiated fibrotic markers integrin, α-smooth muscle actin expression, and collagen IV and apoptotic protein caspase 3 were tested. DM induced early changes starting from week four in the tested variables. At week twelve, in both experiments, valsartan intervention showed a significant reduction in ANG II, ANGPTL2, TLR 4 and integrin expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers. Conclusions Changes leading to DN starts early in the disease course and ANG II reduction decreased the expression of ANGPTL2 and integrin which preserve the glomerular barrier. Blocking ANG II was able to decrease TLR 4 and inflammatory cytokines leading to decreasing DN.
- 24 August 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (9) , 6457-6470
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression
Background Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM) and is associated with early changes in renal angiotensin II (ANG II). These changes were evaluated using ANG II blocker valsartan early from week two of diabetes (experiment I, renoprotective) and late from week nine of diabetes (experiment II, renotherapeutic) to the end of both experiments at week twelve. Methods and results In both experiments, adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, diabetic rats received valsartan treated in experiments I and II. DM effects on urine albumin excretion, blood pressure, and renal ANG II were measured. Urinary nephrin, kidney injury molecule-1 (KIM-1), renal angiopoietin-like protein 2 (ANGPTL2), and toll-like receptor 4 (TLR 4) mRNA expression were tested. DM-initiated fibrotic markers integrin, α-smooth muscle actin expression, and collagen IV and apoptotic protein caspase 3 were tested. DM induced early changes starting from week four in the tested variables. At week twelve, in both experiments, valsartan intervention showed a significant reduction in ANG II, ANGPTL2, TLR 4 and integrin expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers. Conclusions Changes leading to DN starts early in the disease course and ANG II reduction decreased the expression of ANGPTL2 and integrin which preserve the glomerular barrier. Blocking ANG II was able to decrease TLR 4 and inflammatory cytokines leading to decreasing DN.
- Open Access
- 10 March 2021
- Published by Springer Nature in Research Square
Diabetic Nephropathy Progression in type 1 Diabetes: Temporal Renal Angiopoietin-Like Protein 2-Toll-Like Receptor 4 and Role of Early Renal Angiotensin II Inhibition by Valsartan
Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM). DM is associated temporal changes in renal angiotensin II (ANG II) release and multiple mediators leading to DN. These changes were evaluated using early ANG II blocker valsartan as a DN renoprotective drug. Adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, valsartan treated-diabetic rats after 7 days from DM. Other group of diabetic animals assigned to receive late valsartan intervention from week 9 to 12 of DM. The renoprotective effect evaluated at 4th, 8th, 12th weeks. DN effects on urine albumin excretion, blood pressure and renal ANG II were measured. Urinary nephrin and kidney injury molecule-1 biomarkers, renal ANGPTL2, and toll-like receptor 4 (TLR 4) mRNA expression were tested. DN-initiated fibrotic markers integrin, α-smooth muscle expression and collagen IV and apoptotic protein caspase 3 were tested. DM induced changes starting from the 4th week. At 12th week, early valsartan intervention showed a significant reduction in ANG II, ANGPTL2 and TLR 4 expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers, more than the late intervention. Early inhibition of ANG II in diabetes is associated with decrease in ANGPTL2 and TLR 4 proteins and fibrotic changes. This observation helps in understanding DN pathophysiology and its therapeutic approaches.
- 10 March 2021
- Published by Springer Nature in Research Square
Open AccessDiabetic Nephropathy Progression in type 1 Diabetes: Temporal Renal Angiopoietin-Like Protein 2-Toll-Like Receptor 4 and Role of Early Renal Angiotensin II Inhibition by Valsartan
Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM). DM is associated temporal changes in renal angiotensin II (ANG II) release and multiple mediators leading to DN. These changes were evaluated using early ANG II blocker valsartan as a DN renoprotective drug. Adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, valsartan treated-diabetic rats after 7 days from DM. Other group of diabetic animals assigned to receive late valsartan intervention from week 9 to 12 of DM. The renoprotective effect evaluated at 4th, 8th, 12th weeks. DN effects on urine albumin excretion, blood pressure and renal ANG II were measured. Urinary nephrin and kidney injury molecule-1 biomarkers, renal ANGPTL2, and toll-like receptor 4 (TLR 4) mRNA expression were tested. DN-initiated fibrotic markers integrin, α-smooth muscle expression and collagen IV and apoptotic protein caspase 3 were tested. DM induced changes starting from the 4th week. At 12th week, early valsartan intervention showed a significant reduction in ANG II, ANGPTL2 and TLR 4 expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers, more than the late intervention. Early inhibition of ANG II in diabetes is associated with decrease in ANGPTL2 and TLR 4 proteins and fibrotic changes. This observation helps in understanding DN pathophysiology and its therapeutic approaches.
- Open Access
- 28 January 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (2) , 1-34
Upregulation of antioxidant nuclear factor erythroid 2-related factor 2 and its dependent genes associated with enhancing renal ischemic preconditioning renoprotection using levosimendan and cilostazol in an ischemia/reperfusion rat model
Introduction: Ischemic preconditioning (Ipre) provides protection against renal ischemia-reperfusion (I/R) injury with its associated remote organ damage. This study examined the enhancing protective effect of Ipre with levosimendan or cilostazol in I/R-induced kidney and lung injury in a rat model.Material and methods: Rats were divided into: sham-operated, I/R control, Ipre control, I/R + cilostazol or levosimendan and Ipre + cilostazol or levosimendan. Drugs were given 30 min before left renal I/R or 4 cycles of Ipre just before renal ischemia.Results: The Ipre combined with the implemented drugs enhanced physiological antioxidant defense genes including renal nuclear factor erythroid 2-related factor 2 (Nrf2) and its dependent genes heme oxygenase-1 (HO-1) and NADPH-quinone oxidoreductase-1 (NQO-1) and improved malondialdehyde and superoxide dismutase renal tissue levels. The combined effect improved I/R consequences for blood urea, creatinine, and creatinine clearance and improved blood oxygenation and metabolic acidosis. Moreover, the combination improved the renal soluble intercellular adhesion molecule (ICAM), tumor necrosis factor α (TNF-α) and interlukin-6 (IL-6) with histopathological improvement of tubular necrosis with a decrease in the apoptotic marker caspase-3 and an increase in the anti-apoptotic Bcl-2 expression.Conclusions: Cilostazol or levosimendan potentiates the renoprotective effect of Ipre against renal I/R injury, associated with upregulation of antioxidant genes Nrf2, HO-1, and NOQ-1 expression.
- 28 January 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (2) , 1-34
Open AccessUpregulation of antioxidant nuclear factor erythroid 2-related factor 2 and its dependent genes associated with enhancing renal ischemic preconditioning renoprotection using levosimendan and cilostazol in an ischemia/reperfusion rat model
Introduction: Ischemic preconditioning (Ipre) provides protection against renal ischemia-reperfusion (I/R) injury with its associated remote organ damage. This study examined the enhancing protective effect of Ipre with levosimendan or cilostazol in I/R-induced kidney and lung injury in a rat model.Material and methods: Rats were divided into: sham-operated, I/R control, Ipre control, I/R + cilostazol or levosimendan and Ipre + cilostazol or levosimendan. Drugs were given 30 min before left renal I/R or 4 cycles of Ipre just before renal ischemia.Results: The Ipre combined with the implemented drugs enhanced physiological antioxidant defense genes including renal nuclear factor erythroid 2-related factor 2 (Nrf2) and its dependent genes heme oxygenase-1 (HO-1) and NADPH-quinone oxidoreductase-1 (NQO-1) and improved malondialdehyde and superoxide dismutase renal tissue levels. The combined effect improved I/R consequences for blood urea, creatinine, and creatinine clearance and improved blood oxygenation and metabolic acidosis. Moreover, the combination improved the renal soluble intercellular adhesion molecule (ICAM), tumor necrosis factor α (TNF-α) and interlukin-6 (IL-6) with histopathological improvement of tubular necrosis with a decrease in the apoptotic marker caspase-3 and an increase in the anti-apoptotic Bcl-2 expression.Conclusions: Cilostazol or levosimendan potentiates the renoprotective effect of Ipre against renal I/R injury, associated with upregulation of antioxidant genes Nrf2, HO-1, and NOQ-1 expression.
- 1 April 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 872, 172959
Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway
- 1 April 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 872, 172959
Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway
- 13 January 2020
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 466 (1-2) , 45-54
Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance
Insulin resistance (IR) has emerged as one of the main risk factors for renal fibrosis (RF) that represents a common stage in almost all chronic kidney disease. The present study aims to investigate the inhibitory effect of empagliflozin (EMPA “a sodium-glucose co-transporter 2 inhibitor”) and infliximab [IFX “a tumor necrosis factor-α (TNF-α) antibody”] on RF in rats with induced IR. IR was induced by adding 10% fructose in drinking water for 20 weeks. Thereafter, fructose-induced IR rats were concurrently treated with EMPA (30 mg/kg), IFX (1 dose 5 mg/kg), or EMPA + IFX for 4 weeks, in addition to IR control group (received 10% fructose in water) and normal control (NC) group. Rats with IR displayed hyperglycemia, deterioration in kidney functions, glomerulosclerosis, and collagen fiber deposition in renal tissues as compared to NC. This was associated with downregulation of the renal sirtuin 1 (Sirt 1) expression along with higher renal tissue TNF-α and transforming growth factor-β1 (TGF-β1) levels. Both EMPA and IFX significantly modulated the aforementioned fibrotic cytokines, upregulated the renal Sirt 1 expression, and attenuated RF compared to IR control group. Of note, IFX effect was superior to that of EMPA. However, the combination of EMPA and IFX alleviated RF to a greater extent surpassing the monotherapy. This may be attributed to the further upregulation of renal Sirt 1 in addition to the downregulation of fibrotic cytokines. These findings suggest that the combination of EMPA and IFX offers additional benefits and may represent a promising therapeutic option for RF.
- 13 January 2020
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 466 (1-2) , 45-54
Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance
Insulin resistance (IR) has emerged as one of the main risk factors for renal fibrosis (RF) that represents a common stage in almost all chronic kidney disease. The present study aims to investigate the inhibitory effect of empagliflozin (EMPA “a sodium-glucose co-transporter 2 inhibitor”) and infliximab [IFX “a tumor necrosis factor-α (TNF-α) antibody”] on RF in rats with induced IR. IR was induced by adding 10% fructose in drinking water for 20 weeks. Thereafter, fructose-induced IR rats were concurrently treated with EMPA (30 mg/kg), IFX (1 dose 5 mg/kg), or EMPA + IFX for 4 weeks, in addition to IR control group (received 10% fructose in water) and normal control (NC) group. Rats with IR displayed hyperglycemia, deterioration in kidney functions, glomerulosclerosis, and collagen fiber deposition in renal tissues as compared to NC. This was associated with downregulation of the renal sirtuin 1 (Sirt 1) expression along with higher renal tissue TNF-α and transforming growth factor-β1 (TGF-β1) levels. Both EMPA and IFX significantly modulated the aforementioned fibrotic cytokines, upregulated the renal Sirt 1 expression, and attenuated RF compared to IR control group. Of note, IFX effect was superior to that of EMPA. However, the combination of EMPA and IFX alleviated RF to a greater extent surpassing the monotherapy. This may be attributed to the further upregulation of renal Sirt 1 in addition to the downregulation of fibrotic cytokines. These findings suggest that the combination of EMPA and IFX offers additional benefits and may represent a promising therapeutic option for RF.
- 1 October 2019
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 22 (2) , 122-128
Urinary Monocyte Chemoattractant Protein -1 as A Diagnostic Marker of Lupus Nephritis
- 1 October 2019
- Published by Egyptian Knowledge Bank in Suez Canal University Medical Journal
- Vol. 22 (2) , 122-128
Urinary Monocyte Chemoattractant Protein -1 as A Diagnostic Marker of Lupus Nephritis